The Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine, called ivonescimab, improving patient survival — the gold standard outcome of any cancer study.
%20MH%20Testing/Larger%20Header%20Logos/STAT_Main2.png?height=88&upscale=true&name=STAT_Main2.png){kind=small}
%20MH%20Testing/Footer%20Icons/Flipboard-logo.png?width=60&height=60&upscale=true&name=Flipboard-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/X-logo.png?width=60&height=60&upscale=true&name=X-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Linkedin-logo.png?width=60&height=60&upscale=true&name=Linkedin-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Facebook-logo.png?width=60&height=60&upscale=true&name=Facebook-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Youtube-logo.png?width=60&height=60&upscale=true&name=Youtube-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Instagram-logo.png?width=60&height=60&upscale=true&name=Instagram-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Threads-logo.png?width=60&height=60&upscale=true&name=Threads-logo.png){kind=logo}